ReviewCell communication and signaling : CCS2025
Immunomodulatory properties of probiotic extracellular vesicles- do they have the potential to fill the gap in therapeutic strategies for allergies?
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Probiotics and Extracellular Vesicles as Redox Modulators in Wound Healing: From Microbial Therapeutics to Engineered Nanotherapeutic Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Gnotobiotic mouse models as tools for dissecting the role of the microbiota in allergy: contributions from the laboratory of gnotobiology in Nový Hrádek.Folia microbiologica · 2026Review
- Extracellular Vesicles in Allergy: From Cellular Communication to Clinical Implications.Clinical reviews in allergy & immunology · 2026Review
- Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician's Perspective.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Probiotics, widely recognized for their health-promoting properties, have demonstrated efficacy in alleviating allergy symptoms. Recent research highlights that probiotic-derived extracellular vesicles (EVs) exhibit significant immunomodulatory potential, opening new avenues for therapeutic applications. While several immunoregulatory properties of probiotic EVs have been identified, their possible usage in anti-allergy strategies remains in its infancy. This review synthesizes current knowledge on probiotic EVs and explores their therapeutic potential as innovative immunomodulators for allergy prevention and treatment. Probiotic EVs facilitate host-microbiota communication by modulating immune signaling pathways, including receptor interactions, cytokine production, and regulation of tight junction proteins. Intriguingly, probiotic EVs show unique or sometimes even opposing properties compared to their parent bacteria, underscoring their potential as distinct therapeutic agents. Probiotic EVs offer a promising alternative to live bacterial therapies, particularly for vulnerable populations such as immunocompromised individuals and premature infants, where live probiotics may pose safety concerns. This review underscores the need for further research to elucidate the mechanisms of action, biological potential, and limitations of probiotic EVs, while addressing the challenges of translating these findings into effective anti-allergy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.